196 related articles for article (PubMed ID: 25029971)
1. Important role of translational science in rare disease innovation, discovery, and drug development.
Pariser AR; Gahl WA
J Gen Intern Med; 2014 Aug; 29 Suppl 3(Suppl 3):S804-7. PubMed ID: 25029971
[TBL] [Abstract][Full Text] [Related]
2. Challenges of developing and conducting clinical trials in rare disorders.
Kempf L; Goldsmith JC; Temple R
Am J Med Genet A; 2018 Apr; 176(4):773-783. PubMed ID: 28815894
[TBL] [Abstract][Full Text] [Related]
3. Rare diseases research: expanding collaborative translational research opportunities.
Groft SC
Chest; 2013 Jul; 144(1):16-23. PubMed ID: 23880676
[TBL] [Abstract][Full Text] [Related]
4. Rare Diseases: Joining Mainstream Research and Treatment Based on Reliable Epidemiological Data.
Groft SC; Posada de la Paz M
Adv Exp Med Biol; 2017; 1031():3-21. PubMed ID: 29214563
[TBL] [Abstract][Full Text] [Related]
5. New and evolving rare diseases research programs at the National Institutes of Health.
Groft SC; Rubinstein YR
Public Health Genomics; 2013; 16(6):259-67. PubMed ID: 24503586
[TBL] [Abstract][Full Text] [Related]
6. Preparing for the Future of Rare Diseases.
Groft SC; Posada de la Paz M
Adv Exp Med Biol; 2017; 1031():641-648. PubMed ID: 29214596
[TBL] [Abstract][Full Text] [Related]
7. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
8. [A dream becoming reality].
Pouget J
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():7. PubMed ID: 30943152
[No Abstract] [Full Text] [Related]
9. Towards efficiency in rare disease research: what is distinctive and important?
Jia J; Shi T
Sci China Life Sci; 2017 Jul; 60(7):686-691. PubMed ID: 28639105
[TBL] [Abstract][Full Text] [Related]
10. The pooling of manpower and resources through the establishment of European reference networks and rare disease patient registries is a necessary area of collaboration for rare renal disorders.
Parker S
Nephrol Dial Transplant; 2014 Sep; 29 Suppl 4():iv9-14. PubMed ID: 25165190
[TBL] [Abstract][Full Text] [Related]
11. From Nonclinical Research to Clinical Trials and Patient-registries: Challenges and Opportunities in Biomedical Research.
de la Torre Hernández JM; Edelman ER
Rev Esp Cardiol (Engl Ed); 2017 Dec; 70(12):1121-1133. PubMed ID: 28838647
[TBL] [Abstract][Full Text] [Related]
12. Translational science: Newly emerging science in biology and medicine - Lessons from translational research on the natriuretic peptide family and leptin.
Nakao K
Proc Jpn Acad Ser B Phys Biol Sci; 2019; 95(9):538-567. PubMed ID: 31708497
[TBL] [Abstract][Full Text] [Related]
13. The importance of international collaboration for rare diseases research: a European perspective.
Julkowska D; Austin CP; Cutillo CM; Gancberg D; Hager C; Halftermeyer J; Jonker AH; Lau LPL; Norstedt I; Rath A; Schuster R; Simelyte E; van Weely S
Gene Ther; 2017 Sep; 24(9):562-571. PubMed ID: 28440796
[TBL] [Abstract][Full Text] [Related]
14. Recommendations for the design of small population clinical trials.
Day S; Jonker AH; Lau LPL; Hilgers RD; Irony I; Larsson K; Roes KC; Stallard N
Orphanet J Rare Dis; 2018 Nov; 13(1):195. PubMed ID: 30400970
[TBL] [Abstract][Full Text] [Related]
15. An Official American Thoracic Society Workshop Report: Translational Research in Rare Respiratory Diseases.
Kristof AS; Petrof BJ; Hamid Q; Kolb M; Landry JS; MacKenzie A; McCormack FX; Murawski IJ; Moss J; Rauch F; Rosas IO; Shapiro AJ; Smith BM; Thomas DY; Trapnell BC; Young LR; Zariwala MA;
Ann Am Thorac Soc; 2017 Aug; 14(8):1239-1247. PubMed ID: 28763267
[TBL] [Abstract][Full Text] [Related]
16. Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders.
Mulberg AE; Bucci-Rechtweg C; Giuliano J; Jacoby D; Johnson FK; Liu Q; Marsden D; McGoohan S; Nelson R; Patel N; Romero K; Sinha V; Sitaraman S; Spaltro J; Kessler V
Orphanet J Rare Dis; 2019 Feb; 14(1):36. PubMed ID: 30736861
[TBL] [Abstract][Full Text] [Related]
17. The value of research collaborations and consortia in rare cancers.
Blay JY; Coindre JM; Ducimetière F; Ray-Coquard I
Lancet Oncol; 2016 Feb; 17(2):e62-e69. PubMed ID: 26868355
[TBL] [Abstract][Full Text] [Related]
18. Impact of biobanks on research outcomes in rare diseases: a systematic review.
Garcia M; Downs J; Russell A; Wang W
Orphanet J Rare Dis; 2018 Nov; 13(1):202. PubMed ID: 30419920
[TBL] [Abstract][Full Text] [Related]
19. Evidence-based data and rare cancers: The need for a new methodological approach in research and investigation.
Mathoulin-Pélissier S; Pritchard-Jones K
Eur J Surg Oncol; 2019 Jan; 45(1):22-30. PubMed ID: 29526369
[TBL] [Abstract][Full Text] [Related]
20. Progress in molecular biology and translational science addressing the needs of nano-rare patients.
Crooke ST
Prog Mol Biol Transl Sci; 2022; 190(1):127-146. PubMed ID: 36007997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
